Biotech With Groundbreaking Diabetes Treatment Secures CA$7.1M Breakthrough Financing
Record Profits, a Vape Market Landgrab, and a CA$250M Facility Bought for CA$27M
Research Report
Biotech Expands Financing to CA$2M as AI-Driven Cancer Drug Programs Advance
New Data, Analyst Calls, and Pipeline Milestones Put Spotlight on Next Wave of Weight-Loss Drug Developers
Biotech Company Advances Breakthrough Hyperinsulinism Treatment
CleanTech Company Advances FDA-Cleared Solution Toward Big Gains
Technically Oversold with Support, Solid Patents, & A Heavyweight Board: Is This Stock Set to Soar?
Contributed Technical Analyst Opinion
Experts Spotlight a Persistent Barrier in Advanced Cancer Therapies
Rakovina Therapeutics Inc. (RKV:TSX.V) outlined its AI-driven approach to brain-penetrant ATR and mTOR inhibitors during the 9th Annual DNA Damage Response Inhibitors Summit in Boston. The company also reported inbound interest in its kt-3000 series as potential payloads for antibody-drug conjugates.FDA Grants Orphan Drug Status to Experimental Melanoma Therapy After Phase 1 Results
TuHURA Biosciences Inc. (HURA:NASDAQ) said the FDA granted Orphan Drug Designation to IFx-2.0 for stage IIB to stage IV cutaneous melanoma. The designation was based on data from the companys previously completed Phase 1 clinical study.Drug Developer Uncovers Excellent Progress in 200-Patient ALS Study
Biopharmaceutical company MediciNova Inc. (MNOV:NASDAQ) announces that by the end of January, 12 sites in the U.S. have been activated and 100 patients have been enrolled in its studying evaluating its treatment for ALS. Read what one analyst says investors should be looking for from the company in the coming year.Biopharma Reaches 50% Enrollment in New ALS Drug Program
Research Report
MediciNova Inc. (MNOV:NASDAQ) enrolls 100 patients in the SEANOBI Expanded Access Program for MN-166 (ibudilast), noted a D. Boral Capital report. Read on to learn the many potential catalysts ahead for this California-based firm. Biopharmaceutical Co. Looking for Breakthrough in US$987.6M ALS Treatment Market
Biopharmaceutical firm MediciNova Inc. (MNOV:NASDAQ) reports that by the end of January, it has activated 12 sites in the U.S. and enrolled 100 patients in its study assessing its ALS treatment. Discover what one analyst suggests investors should watch for from the company in the upcoming year.Clean Tech Developer Sees Massive Opportunity in PFAS Treatment
BioLargo Inc. (BLGO:OTCQX) announces that its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system has been installed in New Jersey. Find out why the company sees massive upside for its products.Environmental Firm Finds High-Value Position in PFAS Remediation Industry
BioLargo Inc. (BLGO:OTCQX) has announced the installation of its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system in New Jersey. Discover why the company anticipates significant potential for its products.Report of FDA Drug Approval Delay is 'Likely Noise': Analyst
Research Report
Disc Medicine Inc.'s (IRON:NASDAQ) chances of bitopertin getting approved remain unaltered by the claims in a recent article, noted an H.C. Wainwright & Co. report. Read on to learn the reasons behind this opinion of the investment bank. Biotech Co. Expands Testing Tied to its Cell Pouch Bio-hybrid Organ
Research Report
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) seeks to determine how a newly developed immunosuppressive agent and, separately, how a different type of islet will work in conjunction with cell implantation via its proven Cell Pouch Bio-hybrid Organ, noted a Leede Financial Inc. report. Read on to learn more about what this Speculative Buy-rated company is working on. 
Streetwise Key Charts
